--- schema_version: "secwatch.filing_event.v1" accession: "0001104659-23-072241" form_type: "8-K" ticker: null cik: "0000855654" company_name: "ImmunoGen, Inc." filed_at: "2023-06-16T23:59:59+00:00" generated_at: "2026-06-13T23:26:39.804364+00:00" event_type: "other" sentiment: "neutral" materiality_score: 0.2 calibrated_materiality_score: 0.2 confidence: "high" source: SEC EDGAR --- # ImmunoGen annual meeting: directors elected, say-on-pay approved, bylaws amended ## Summary - Shareholders fixed board size at nine: 156,535,922 for, 435,617 against, 678,206 abstain. - Nine directors elected; highest vote for Mark J. Enyedy (155,483,440 for), lowest for Dean J. Mitchell (108,169,736 for, 49,480,009 withheld). - Advisory say-on-pay approved: 151,434,309 for (96.1% of votes cast); frequency vote selects one year with 155,975,455 votes (99.5% of votes cast). - Ratification of Ernst & Young LLP as auditor: 177,531,372 for, 4,513,445 against, 774,118 abstain. - Bylaws amended effective June 14, 2023 to incorporate universal proxy rules (Rule 14a-19) and enhance shareholder nomination/disclosure procedures. ## SEC filing metadata - accession: 0001104659-23-072241 - form_type: 8-K - cik: 0000855654 - company_name: ImmunoGen, Inc. - filed_at: 2023-06-16T23:59:59+00:00 - event_type: other - sentiment: neutral - materiality_score: 0.2 - calibrated_materiality_score: 0.2 - confidence: high - sec_items: 5.03, 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/855654/000110465923072241/0001104659-23-072241-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/855654/000110465923072241/tm2318847d1_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001104659-23-072241 - JSON: https://secwatch.observer/filing/0001104659-23-072241.json - Plain text: https://secwatch.observer/filing/0001104659-23-072241.txt ## Key facts - Governance Changes ImmunoGen, Inc.: Amended and restated bylaws to enhance procedural mechanics for shareholder nominations and submissions, reflect universal proxy rules, and make other changes (effective 2023-06-14). - Change: bylaw amendment - Effective: 2023-06-14 source text: On June 14, 2023, the Board of Directors (the “Board”) of ImmunoGen, Inc. (the “Company”) approved an amendment and restatement of the Company’s by-laws (following such amendment and restatement, the “Amended and Restated By-Laws”). evidence_url: https://www.sec.gov/Archives/edgar/data/855654/000110465923072241/0001104659-23-072241-index.htm - Shareholder Votes ImmunoGen, Inc. shareholders approved Advisory vote on frequency of future say-on-pay votes at the 2023-06-14 meeting. - Proposal: say on pay frequency - Outcome: passed - Meeting: 2023-06-14 source text: At the 2023 Annual Meeting, shareholders voted, on an advisory basis, on the frequency of future shareholder advisory votes on compensation of the Company’s named executive officers as follows: One Year: 155,975,455 Two Years: 140,845 Three Years: 712,387 Abstain: 821,058 Broker Non-Votes: 25,169,190 evidence_url: https://www.sec.gov/Archives/edgar/data/855654/000110465923072241/0001104659-23-072241-index.htm - Shareholder Votes ImmunoGen, Inc. shareholders approved Fix number of directors at nine at the 2023-06-14 meeting. - Outcome: passed - Meeting: 2023-06-14 source text: At the 2023 annual meeting of shareholders of the Company held on June 14, 2023 (the “2023 Annual Meeting”), shareholders fixed the number of directors constituting the full Board of the Company at nine according to the following vote: For: 156,535,922 Against: 435,617 Abstain: 678,206 Broker Non-Votes: 25,169,190 evidence_url: https://www.sec.gov/Archives/edgar/data/855654/000110465923072241/0001104659-23-072241-index.htm - Shareholder Votes ImmunoGen, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2023-06-14 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-06-14 source text: At the 2023 Annual Meeting, shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 according to the following vote: For: 177,531,372 Against: 4,513,445 Abstain: 774,118 Broker Non-Votes: 0 evidence_url: https://www.sec.gov/Archives/edgar/data/855654/000110465923072241/0001104659-23-072241-index.htm - Shareholder Votes ImmunoGen, Inc. shareholders approved Election of nine directors at the 2023-06-14 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-06-14 source text: At the 2023 Annual Meeting, shareholders elected nine directors according to the following vote: FOR WITHHELD BROKER NON-VOTES Stuart A. Arbuckle 143,760,206 13,889,539 25,169,190 Mark J. Enyedy 155,483,440 2,166,305 25,169,190 Mark A. Goldberg, M.D. 153,755,304 3,894,441 25,169,190 Tracey L. McCain, Esq. 143,854,594 13,795,151 25,169,190 Stephen C. McCluski 154,413,361 3,236,384 25,169,190 Dean J. Mitchell 108,169,736 49,480,009 25,169,190 Kristine Peterson 139,924,924 17,724,821 25,169,190 Helen M. Thackray, M.D. 155,386,213 2,263,532 25,169,190 Richard J. Wallace 154,673,900 2,975,845 25,169,190 evidence_url: https://www.sec.gov/Archives/edgar/data/855654/000110465923072241/0001104659-23-072241-index.htm - Shareholder Votes ImmunoGen, Inc. shareholders approved Advisory vote on compensation paid to named executive officers (say-on-pay) at the 2023-06-14 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2023-06-14 source text: At the 2023 Annual Meeting, shareholders voted, on an advisory basis, on the compensation paid to our named executive officers, as described in the Proxy Statement (referred to as the “say-on-pay vote”) as follows: For: 151,434,309 Against: 4,809,048 Abstain: 1,406,388 Broker Non-Votes: 25,169,190 evidence_url: https://www.sec.gov/Archives/edgar/data/855654/000110465923072241/0001104659-23-072241-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.